Sarah Boyce - Net Worth and Insider Trading

Sarah Boyce Net Worth

The estimated net worth of Sarah Boyce is at least $14 Million dollars as of 2024-11-05. Sarah Boyce is the President and CEO of Avidity Biosciences Inc and owns about 297,163 shares of Avidity Biosciences Inc (RNA) stock worth over $13 Million. Sarah Boyce is the Director of OmniAb Inc and owns about 88,437 shares of OmniAb Inc (OABI) stock worth over $397,967. Sarah Boyce is also the President of Akcea Therapeutics Inc and owns about 19,888 shares of Akcea Therapeutics Inc (AKCA) stock worth over $361,365. Besides these, Sarah Boyce also holds Ionis Pharmaceuticals Inc (IONS) , PhenomeX Inc (CELL) . Details can be seen in Sarah Boyce's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sarah Boyce has not made any transactions after 2024-09-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Sarah Boyce

Sarah Boyce Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sarah Boyce owns 7 companies in total, including PhenomeX Inc (CELL) , Avidity Biosciences Inc (RNA) , and Ligand Pharmaceuticals Inc (LGND) among others .

Click here to see the complete history of Sarah Boyce’s form 4 insider trades.

Insider Ownership Summary of Sarah Boyce

Ticker	Comapny	Transaction Date	Type of Owner
CELL	PhenomeX Inc	2021-03-01	director
RNA	Avidity Biosciences Inc	2024-09-23	director & President and CEO
LGND	Ligand Pharmaceuticals Inc	2019-10-15	director
		2019-07-15	director & President
		2018-01-16	Chief Business Officer
		2022-11-01	director
		2022-11-10	director

Sarah Boyce Latest Holdings Summary

Sarah Boyce currently owns a total of 5 stocks. Among these stocks, Sarah Boyce owns 297,163 shares of Avidity Biosciences Inc (RNA) as of September 23, 2024, with a value of $13 Million and a weighting of 92.26%. Sarah Boyce owns 88,437 shares of OmniAb Inc (OABI) as of November 10, 2022, with a value of $397,967 and a weighting of 2.79%. Sarah Boyce also owns 19,888 shares of Akcea Therapeutics Inc (AKCA) as of July 15, 2019, with a value of $361,365 and a weighting of 2.53%. The other 2 stocks Ionis Pharmaceuticals Inc (IONS) , PhenomeX Inc (CELL) have a combined weighting of 2.42% among all his current holdings.

Latest Holdings of Sarah Boyce

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RNA	Avidity Biosciences Inc	2024-09-23	297,163	44.36	13,182,151
OABI	OmniAb Inc	2022-11-10	88,437	4.50	397,967
AKCA	Akcea Therapeutics Inc	2019-07-15	19,888	18.17	361,365
IONS	Ionis Pharmaceuticals Inc	2018-01-16	8,931	38.78	346,344
CELL	PhenomeX Inc	2021-03-01	0	1.00	0

Holding Weightings of Sarah Boyce

Sarah Boyce Form 4 Trading Tracker

According to the SEC Form 4 filings, Sarah Boyce has made a total of 13 transactions in Avidity Biosciences Inc (RNA) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Avidity Biosciences Inc is the sale of 32,880 shares on September 23, 2024, which brought Sarah Boyce around $1 Million.

According to the SEC Form 4 filings, Sarah Boyce has made a total of 1 transactions in OmniAb Inc (OABI) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 36,000 shares on November 10, 2022, which cost Sarah Boyce around $101,520.

According to the SEC Form 4 filings, Sarah Boyce has made a total of 0 transactions in Akcea Therapeutics Inc (AKCA) over the past 5 years. The most-recent trade in Akcea Therapeutics Inc is the sale of 1,819 shares on July 15, 2019, which brought Sarah Boyce around $42,783.

More details on Sarah Boyce's insider transactions can be found in the Insider Trading History of Sarah Boyce table.

Insider Trading History of Sarah Boyce

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sarah Boyce Trading Performance

GuruFocus tracks the stock performance after each of Sarah Boyce's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sarah Boyce is 28.31%. GuruFocus also compares Sarah Boyce's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sarah Boyce within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Sarah Boyce's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Sarah Boyce

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	17.55
Relative Return to S&P 500(%)	18.11

Sarah Boyce Ownership Network

Ownership Network List of Sarah Boyce

No Data

Ownership Network Relation of Sarah Boyce

Sarah Boyce Owned Company Details

What does PhenomeX Inc do?

Who are the key executives at PhenomeX Inc?

Sarah Boyce is the director of PhenomeX Inc. Other key executives at PhenomeX Inc include Chief Financial Officer Mehul Joshi , director & Chief Executive Officer Siddhartha Kadia , and 10 percent owner Bird Mergersub Corp .

PhenomeX Inc (CELL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhenomeX Inc (CELL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhenomeX Inc (CELL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhenomeX Inc (CELL)'s detailed insider trading history can be found in Insider Trading Tracker table.

PhenomeX Inc Insider Transactions

No Available Data

What does Avidity Biosciences Inc do?

Who are the key executives at Avidity Biosciences Inc?

Sarah Boyce is the director & President and CEO of Avidity Biosciences Inc. Other key executives at Avidity Biosciences Inc include Chief Scientific Officer Arthur A Levin , Chief Human Resources Officer Teresa Mccarthy , and Chief Technical Officer W. Michael Flanagan .

Avidity Biosciences Inc (RNA) Insider Trades Summary

Over the past 18 months, Sarah Boyce made 10 insider transaction in Avidity Biosciences Inc (RNA) with a net sale of 622,046. Other recent insider transactions involving Avidity Biosciences Inc (RNA) include a net sale of 189,500 shares made by Arthur A Levin , a net sale of 243,599 shares made by Michael F Maclean , and a net sale of 213,129 shares made by W. Michael Flanagan .

In summary, during the past 3 months, insiders sold 379,437 shares of Avidity Biosciences Inc (RNA) in total and bought 0 shares, with a net sale of 379,437 shares. During the past 18 months, 1,373,356 shares of Avidity Biosciences Inc (RNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,373,356 shares.

Avidity Biosciences Inc (RNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avidity Biosciences Inc Insider Transactions

No Available Data

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Sarah Boyce is the director of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , VP & Finance and CFO Matthew E Korenberg , and Chief Financial Officer Octavio Espinoza .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Sarah Boyce made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 70,748 shares made by Matthew E Korenberg , a net sale of 14,708 shares made by Octavio Espinoza , and a net sale of 13,500 shares made by Andrew Reardon .

In summary, during the past 3 months, insiders sold 57,925 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 2,500 shares, with a net sale of 55,425 shares. During the past 18 months, 119,043 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 6,500 shares were bought by its insiders, resulting in a net sale of 112,543 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

What does Akcea Therapeutics Inc do?

Who are the key executives at Akcea Therapeutics Inc?

Sarah Boyce is the director & President of Akcea Therapeutics Inc. Other key executives at Akcea Therapeutics Inc include director & Chief Executive Officer Damien Mcdevitt , Chief Medical Officer William T. Andrews , and Chief Financial Officer Michael Dennis Price .

Akcea Therapeutics Inc (AKCA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akcea Therapeutics Inc (AKCA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akcea Therapeutics Inc (AKCA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akcea Therapeutics Inc (AKCA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akcea Therapeutics Inc Insider Transactions

No Available Data

What does Ionis Pharmaceuticals Inc do?

Who are the key executives at Ionis Pharmaceuticals Inc?

Sarah Boyce is the Chief Business Officer of Ionis Pharmaceuticals Inc. Other key executives at Ionis Pharmaceuticals Inc include SVP & Research Eric Swayze , Senior Vice President Richard S Geary , and EVP & Corp and Development Ops Brian Birchler .

Ionis Pharmaceuticals Inc (IONS) Insider Trades Summary

Over the past 18 months, Sarah Boyce made no insider transaction in Ionis Pharmaceuticals Inc (IONS). Other recent insider transactions involving Ionis Pharmaceuticals Inc (IONS) include a net sale of 181,397 shares made by Brett P Monia , a net sale of 35,600 shares made by Richard S Geary , and a net sale of 60,168 shares made by C Frank Bennett .

In summary, during the past 3 months, insiders sold 704 shares of Ionis Pharmaceuticals Inc (IONS) in total and bought 0 shares, with a net sale of 704 shares. During the past 18 months, 614,196 shares of Ionis Pharmaceuticals Inc (IONS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 614,196 shares.

Ionis Pharmaceuticals Inc (IONS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ionis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Avista Public Acquisition Corp II do?

Who are the key executives at Avista Public Acquisition Corp II?

Sarah Boyce is the director of Avista Public Acquisition Corp II. Other key executives at Avista Public Acquisition Corp II include director & 10 percent owner David F Burgstahler , director & 10 percent owner Thompson Dean , and director & 10 percent owner Avista Acquisition Gp Llc Ii .

Avista Public Acquisition Corp II (AHPA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Avista Public Acquisition Corp II (AHPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Avista Public Acquisition Corp II (AHPA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Avista Public Acquisition Corp II (AHPA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avista Public Acquisition Corp II Insider Transactions

No Available Data

What does OmniAb Inc do?

Who are the key executives at OmniAb Inc?

Sarah Boyce is the director of OmniAb Inc. Other key executives at OmniAb Inc include director & President & CEO Matthew W Foehr , EVP & Finance and CFO Kurt A Gustafson , and See Remarks Charles S Berkman .

OmniAb Inc (OABI) Insider Trades Summary

Over the past 18 months, Sarah Boyce made no insider transaction in OmniAb Inc (OABI). Other recent insider transactions involving OmniAb Inc (OABI) include a net purchase of 1,360,000 shares made by Matthew W Foehr , a net sale of 60,000 shares made by John L Higgins , and a net sale of 18,803 shares made by Kurt A Gustafson .

In summary, during the past 3 months, insiders sold 0 shares of OmniAb Inc (OABI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 85,757 shares of OmniAb Inc (OABI) were sold and 1,360,000 shares were bought by its insiders, resulting in a net purchase of 1,274,243 shares.

OmniAb Inc (OABI)'s detailed insider trading history can be found in Insider Trading Tracker table.

OmniAb Inc Insider Transactions

No Available Data

Sarah Boyce Mailing Address

Above is the net worth, insider trading, and ownership report for Sarah Boyce. You might contact Sarah Boyce via mailing address: C/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad Ca 92010.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.